R&D Expenses
$251.80M
TTM · Period ending: · USD

RPRX R&D Expenses
What is r&d expenses?
Research and development spending.
RPRX r&d expenses history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 452,000,000 | |
| 2,000,000 | |
| 52,000,000 | |
| 177,106,000 | |
| 200,084,000 | |
| 26,289,000 | |
| 83,036,000 | |
| 392,609,000 | |
| 117,866,000 | |
| 91,021,000 | |
| 98,381,000 |
Frequently asked questions: RPRX r&d expenses
What is Royalty Pharma plc (RPRX)'s current r&d expenses?
Royalty Pharma plc (RPRX)'s latest reported r&d expenses (TTM) is $251.80M as of Sep 30, 2026. Research and development spending.
How much historical r&d expenses data is available for RPRX?
Stock Alarm Pro provides 11 dated annual fiscal periods observations for Royalty Pharma plc (RPRX)'s r&d expenses, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.
How can I compare RPRX's r&d expenses to peers or set an alert?
You can open RPRX's r&d expenses in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on RPRX delivered by push, email, or phone call.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance